---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-076795"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:38:05.533731+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics in-licenses Dr. Reddy's Abatacept biosimilar for COYA 302; $350K upfront, up to $22.7M milestones

## Summary
- Exclusive License and Supply Agreement with Dr. Reddy's for Abatacept biosimilar, effective April 1, 2023.
- Upfront payment of $350,000; potential development, regulatory and sales milestones up to ~$22.7 million.
- COYA 302 combines Coya's low-dose IL-2 (COYA 301) with the biosimilar for neurodegenerative diseases.
- Coya responsible for development; Dr. Reddy's for manufacture and supply of biosimilar.
- Agreement covers U.S., Canada, Mexico, South America, EU, UK, Japan; cross-license for COYA 301 in other territories.

## SEC filing metadata
- accession: 0001193125-23-076795
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/0001193125-23-076795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/d429716d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-076795
- JSON: https://secwatch.observer/filing/0001193125-23-076795.json
- Plain text: https://secwatch.observer/filing/0001193125-23-076795.txt

## Key facts
- Material Agreements
  Coya Therapeutics, Inc. entered into License Agreement with Dr. Reddy's Laboratories Limited valued at $350,000 (effective 2023-03-16).
  - Action: entry
  - Agreement: license
  - Counterparty: Dr. Reddy's Laboratories Limited
  - Value: $350,000
  - Effective: 2023-03-16
  source text: On March16, 2023, Coya Therapeutics, Inc. (the “Company”) entered into an exclusive License and Supply Agreement (the “License Agreement”) with Dr. Reddy’s Laboratories Limited (“DRL”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312523076795/0001193125-23-076795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.